13073_2015_233_MOESM10_ESM.pdf (244.25 kB)
Additional file 10: of HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
journal contribution
posted on 2015-10-24, 05:00 authored by Andrew Teschendorff, Shih-Han Lee, Allison Jones, Heidi Fiegl, Marie Kalwa, Wolfgang Wagner, Kantaraja Chindera, Iona Evans, Louis Dubeau, Arturo Orjalo, Hugo Horlings, Lukas Niederreiter, Arthur Kaser, Winnie Yang, Ellen Goode, Brooke Fridley, Richard Jenner, Els Berns, Elisabeth Wik, Helga Salvesen, G. Wisman, Ate van der Zee, Ben Davidson, Claes Trope, Sandrina Lambrechts, Ignace Vergote, Hilary Calvert, Ian Jacobs, Martin WidschwendterKaplan-Meier survival estimates in patients from the BERGEN set who received no chemotherapy (untreated group, n = 9) (a) or carboplatin-based chemotherapy (n = 40) (b) and stratified according to HOTAIR expression. Patients (n = 49) treated in Bergen (Norway) and whose cancers had >25 % stroma component were analyzed; 8, 2, 34 and 5 had stage 1, 2, 3 and 4 disease, respectively; 32, 6, 9 and 2 had a serous, mucinous, endometrioid and clear cell cancer, respectively. In the untreated group, significantly more patients had stage 1 disease (44 % versus 10 % in the carboplatin group) and no residual disease after primary surgery (75 % versus 38 % in the carboplatin group). The top tertile expressing samples were deemed as high (positive) HOTAIR expressors and compared with low/absent (negative) HOTAIR expressors. There is no significant difference between high and low HOTAIR expressors with regards to grade, stage or residual disease. Comparing HOTAIR-positive with HOTAIR-negative patients, the hazard ratio is 2.55 (95 % confidence interval 1.14–5.68), P value 0.018. (PDF 244 kb)
